Open access · CC-BY
via OpenAlex
Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition
Mehdi Razazian, Sheyda Bahiraii, Azmat Sohail, Markus Mandl, Isratul Jannat, Georg F. Beilhack, Ioana Alesutan, Jakob G. J. Voelkl
Aging · 2025 · ▲ 4 citations
Abstract
Medial vascular calcification is highly prevalent in advanced age and chronic kidney disease (CKD), where it is associated with increased risk for cardiovascular events and mortality. Vascular smooth muscle cells (VSMCs) actively regulate this process, which can be augmented by inflammation and cellular senescence(definition). Thus, the present study investigated the impact of fisetin, a flavonol with anti-inflammatory and senolytic properties, on VSMC calcification. Fisetin treatment suppressed calcific marker expression and calcification of VSMCs as well as p38 MAPK phosphorylation induced by pro-calcific conditions. These effects were abolished by silencing of dual-specificity phosphatase 1 (DUSP1), a negative regulator of p38 MAPK activity. Moreover, knockdown of DUSP1 alone was sufficient to increase calcific marker expression in VSMCs, effects blunted by pharmacological p38 MAPK inhibition. Accordingly, DUSP1 knockdown aggravated calcification of VSMCs during pro-calcific conditions. In addition, fisetin ameliorated the effects of uremic conditions in VSMCs exposed to serum from dialysis patients. Fisetin also inhibited vascular calcification as well as calcific marker expression ex vivo in mouse aortic explants exposed to high phosphate and in vivo in a cholecalciferol overload mouse model. In conclusion, fisetin acts as a potent anti-calcific agent during VSMC calcification, an effect involving DUSP1-mediated regulation of p38 MAPK-dependent pro-calcific signaling.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.206233
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Razazian, M., Bahiraii, S., Sohail, A., Mandl, M., Jannat, I., Beilhack, G.F., Alesutan, I., & Voelkl, J.G.J. (2025). Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition. <em>Aging</em>. https://doi.org/10.18632/aging.206233
Vancouver
Razazian M, Bahiraii S, Sohail A, Mandl M, Jannat I, Beilhack GF, et al. Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition. Aging. 2025. doi:10.18632/aging.206233.
BibTeX
@article{mehdi2025Fiseti,
title = {Fisetin ameliorates vascular smooth muscle cell calcification via DUSP1-dependent p38 MAPK inhibition},
author = {Mehdi Razazian and Sheyda Bahiraii and Azmat Sohail and Markus Mandl and Isratul Jannat and Georg F. Beilhack and Ioana Alesutan and Jakob G. J. Voelkl},
journal = {Aging},
year = {2025},
doi = {10.18632/aging.206233},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
European Heart Journal 2026
Open access · OA
Attenuation of medial arterial calcification by senescent vascular smooth muscle cell clearance: a uPAR-targeted senolytic therapy
bioRxiv (Cold Spring Harbor Laboratory) 2025
Preprint · CC-BY
Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12
2023
Open access · CC-BY
Analysis of Somatic Mutations in Senescent Cells Using Single-Cell Whole-Genome Sequencing
Cardiovascular Research 2024
Open access · OA
The role of cellular senescence in profibrillatory atrial remodelling associated with cardiac pathology
Aging Cell 2021
Open access · CC-BY
Spermidine inhibits vascular calcification in chronic kidney disease through modulation of SIRT1 signaling pathway
Frontiers in Cardiovascular Medicine 2022
Open access · CC-BY